ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
60,433.58
-4.15%
S&P 500
5,215.70
0.03%
Dow Jones
39,475.92
0.22%
US Dollar vs Yen
155.793
0.26%
Brent Oil
82.71
-1.48%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. イギリス
  5. LSE
  6. Hutchmed (china) Limited (HCM)

  7. Hutchmed (china) Limited (HCM) ニュース

HCM

Hutchmed (china) (HCM)

Hutchmed (china) Limited
から:
次の項目別のソート:
 Showing the most relevant articles for your search:LSE:HCM
日付受信時刻ニュースソース見出しコード企業名
2024/05/1021 : 00RNS Regulatory NewsHutchmed (China) Limited Result of AGMLSE:HCMHutchmed (china) Limited
2024/05/0817 : 30RNS Regulatory NewsHutchmed (China) Limited Directorate ChangeLSE:HCMHutchmed (china) Limited
2024/04/2700 : 09Alliance NewsAlliance NewsHutchmed notes CHMP's positive opinion for fruiquintinib approvalLSE:HCMHutchmed (china) Limited
2024/04/2621 : 30RNS Regulatory NewsHutchmed (China) Limited Positive CHMP Opinion for FruquintinibLSE:HCMHutchmed (china) Limited
2024/04/2217 : 30RNS Regulatory NewsHutchmed (China) Limited Vesting of Awards Under the LTIPLSE:HCMHutchmed (china) Limited
2024/04/0817 : 30RNS Regulatory NewsHutchmed (China) Limited 2023 Annual Report and Notice of AGMLSE:HCMHutchmed (china) Limited
2024/04/0517 : 30RNS Non-RegulatoryHutchmed (China) Limited Data to be Presented at AACR Congress 2024LSE:HCMHutchmed (china) Limited
2024/04/0218 : 32Alliance NewsAlliance NewsHutchmed endometrial cancer treatment application accepted for reviewLSE:HCMHutchmed (china) Limited
2024/04/0215 : 00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED and Innovent Announce NDA AcceptanceLSE:HCMHutchmed (china) Limited
2024/03/2820 : 08Alliance NewsAlliance NewsHutchmed lung cancer treatment accepted for review in ChinaLSE:HCMHutchmed (china) Limited
2024/03/2816 : 00RNS Non-RegulatoryHutchmed (China) Limited Savolitinib sNDA Accepted in ChinaLSE:HCMHutchmed (china) Limited
2024/03/2219 : 09Alliance NewsAlliance NewsHutchmed begins registration stage for sovleplenib phase 2/3 trialLSE:HCMHutchmed (china) Limited
2024/03/2216 : 16Alliance NewsAlliance News*CORRECT: Hutchmed China initiates registration for phase 3 trials of sovleplenibLSE:HCMHutchmed (china) Limited
2024/03/2216 : 00RNS Non-RegulatoryHutchmed (China) Limited Initiation of Registration Stage of P2/3 TrialLSE:HCMHutchmed (china) Limited
2024/03/1418 : 00RNS Regulatory NewsHutchmed (China) Limited LTIP and Share Option SchemeLSE:HCMHutchmed (china) Limited
2024/03/0517 : 30RNS Regulatory NewsHutchmed (China) Limited Vesting of awards under the LTIPLSE:HCMHutchmed (china) Limited
2024/02/2902 : 31Alliance NewsAlliance NewsEARNINGS: Hutchmed revenue surges, Craven House's loss widensLSE:HCMHutchmed (china) Limited
2024/02/2821 : 45RNS Non-RegulatoryHutchmed (China) Limited Publication of Form 20-FLSE:HCMHutchmed (china) Limited
2024/02/2820 : 30RNS Regulatory NewsHutchmed (China) Limited 2023 Full Year Results and Business UpdatesLSE:HCMHutchmed (china) Limited
2024/02/0718 : 50Alliance NewsAlliance NewsHutchmed hails fruquintinib trial results for gastric cancer treatmentLSE:HCMHutchmed (china) Limited
2024/02/0716 : 00RNS Non-RegulatoryHutchmed (China) Limited Presentation of Phase III Data on FruquintinibLSE:HCMHutchmed (china) Limited
2024/02/0218 : 52Alliance NewsAlliance NewsHutchmed says Inmagene exercises option to licence drug candidatesLSE:HCMHutchmed (china) Limited
2024/02/0217 : 37RNS Non-RegulatoryHutchmed (China) Limited Inmagene Exercises Option for Two Drug CandidatesLSE:HCMHutchmed (china) Limited
2024/02/0117 : 30RNS Regulatory NewsHutchmed (China) Limited HUTCHMED to Announce 2023 Final ResultsLSE:HCMHutchmed (china) Limited
2024/01/3018 : 20Alliance NewsAlliance NewsHutchmed celebrates cancer drug approval in hometown of Hong KongLSE:HCMHutchmed (china) Limited
2024/01/3016 : 12RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Receives Marketing Approval in Hong KongLSE:HCMHutchmed (china) Limited
2024/01/1119 : 17Alliance NewsAlliance NewsTOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureauLSE:HCMHutchmed (china) Limited
2024/01/1116 : 00RNS Non-RegulatoryHutchmed (China) Limited Sovleplenib NDA Granted Priority Review in ChinaLSE:HCMHutchmed (china) Limited
2023/12/2917 : 30UK RegulatoryHutchmed (China) Limited Blocklisting Six Monthly ReturnLSE:HCMHutchmed (china) Limited
2023/12/2917 : 30UK RegulatoryHutchmed (China) Limited Total Voting RightsLSE:HCMHutchmed (china) Limited
 Showing the most relevant articles for your search:LSE:HCM

最近閲覧した銘柄

COIN
LWFGBP
TSX
BDI
Black Diamond
COIN
PLOWETH
PLOW Token
COIN
KINETH
KIN
EU
BQPEJ
Postal Bnk 0.00% 15/11/28
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有